| Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non–small cell lung cancer patients Z Yang, N Yang, Q Ou, Y Xiang, T Jiang, X Wu, H Bao, X Tong, X Wang, ... Clinical Cancer Research 24 (13), 3097-3107, 2018 | 410 | 2018 |
| Nuclear Receptor DHR4 Controls the Timing of Steroid Hormone Pulses During Drosophila Development Q Ou, A Magico, K King-Jones PLoS biology 9 (9), e1001160, 2011 | 144 | 2011 |
| Genes associated with increased brain metastasis risk in non–small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non–small … H Wang, Q Ou, D Li, T Qin, H Bao, X Hou, K Wang, F Wang, Q Deng, ... Cancer 125 (20), 3535-3544, 2019 | 94 | 2019 |
| The insect prothoracic gland as a model for steroid hormone biosynthesis and regulation Q Ou, J Zeng, N Yamanaka, C Brakken-Thal, MB O’Connor, K King-Jones Cell reports 16 (1), 247-262, 2016 | 91 | 2016 |
| What goes up must come down: transcription factors have their say in making ecdysone pulses Q Ou, K King-Jones Current topics in developmental biology 103, 35-71, 2013 | 87 | 2013 |
| A Drosophila genome-wide screen identifies regulators of steroid hormone production and developmental timing ET Danielsen, ME Moeller, N Yamanaka, Q Ou, JM Laursen, ... Developmental cell 37 (6), 558-570, 2016 | 83 | 2016 |
| Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib Y Liu, Y Li, Q Ou, X Wu, X Wang, YW Shao, J Ying Lung Cancer 118, 1-5, 2018 | 64 | 2018 |
| Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: results from a large-scale survey of NTRK1 fusions in Chinese patients with lung cancer H Xia, X Xue, H Ding, Q Ou, X Wu, M Nagasaka, YW Shao, X Hu, SHI Ou Clinical lung cancer 21 (3), 247-254, 2020 | 58 | 2020 |
| Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer Y Yu, Q Ou, X Wu, H Bao, Y Ding, YW Shao, S Lu Lung Cancer 127, 19-24, 2019 | 47 | 2019 |
| Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas Y Jin, X Shi, J Zhao, Q He, M Chen, J Yan, Q Ou, X Wu, YW Shao, X Yu Lung Cancer 124, 110-116, 2018 | 46 | 2018 |
| Glycogen branching enzyme controls cellular iron homeostasis via Iron Regulatory Protein 1 and mitoNEET N Huynh, Q Ou, P Cox, R Lill, K King-Jones Nature communications 10 (1), 5463, 2019 | 44 | 2019 |
| Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use F Chen, D Pang, H Guo, Q Ou, X Wu, X Jiang, X Wei, S Liu, L Huang, ... Cancer Medicine 9 (22), 8676-8684, 2020 | 36 | 2020 |
| Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC J Wang, X Li, X Xue, Q Ou, X Wu, Y Liang, X Wang, M You, YW Shao, ... International Journal of Cancer 144 (11), 2677-2682, 2019 | 36 | 2019 |
| Mutation profiling of malignant lymphoma by next-generation sequencing of circulating cell-free DNA P Sun, C Chen, Y Xia, Y Wang, PP Liu, XW Bi, YW Shao, QX Ou, X Wu, ... Journal of Cancer 10 (2), 323, 2019 | 36 | 2019 |
| Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing M Cui, Y Han, P Li, J Zhang, Q Ou, X Tong, R Zhao, N Dong, X Wu, W Li, ... Molecular Oncology 14 (11), 2787-2795, 2020 | 34 | 2020 |
| Cooperative Control of Ecdysone Biosynthesis in Drosophila by Transcription Factors Séance, Ouija Board, and Molting Defective O Uryu, Q Ou, T Komura-Kawa, T Kamiyama, M Iga, M Syrzycka, K Hirota, ... Genetics 208 (2), 605-622, 2018 | 33 | 2018 |
| NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability H Wang, ZW Li, Q Ou, X Wu, M Nagasaka, Y Shao, SHI Ou, Y Yang Cancer Medicine 11 (13), 2541-2549, 2022 | 27 | 2022 |
| Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer H Wen, Z Feng, Y Ma, R Liu, Q Ou, Q Guo, Y Shen, X Wu, Y Shao, H Bao, ... BMC cancer 22 (1), 550, 2022 | 24 | 2022 |
| Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing. Q Ou, X Wu, H Bao, X Tong, X Wang, X Zhang, Z Chang, Y Mao, Y Shao, ... Journal of Clinical Oncology 35 (15_suppl), 2572-2572, 2017 | 23 | 2017 |
| The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients Y Yang, T Zhang, J Wang, J Wang, Y Xu, X Zhao, Q Ou, Y Shao, X Wang, ... Molecular Cancer 21 (1), 117, 2022 | 21 | 2022 |
